Peditrace®

(zinc, copper, manganese, selenium, fluoride, iodine)

For GB healthcare professionals only. This content contains promotional and brand information.
 
Scroll down for prescribing information for micronutrient parenteral nutrition (PN) products and further product information. Adverse event reporting details are available at the bottom of this webpage.

​A trace element supplement for parenteral nutrition in infants and children.

PN should be monitored, and doses adjusted according to individual patient response. Please refer to the Summary of Product Characteristics before prescribing.

Please note product image is for illustrative purposes only and labelling on actual products may appear differently.
 

Filename
Prescribing information parenteral nutrition micronutrients.pdf
Size
150 KB
Format
pdf
PN Micronutrient Prescribing Information

Details

 

  • Peditrace is intended to meet the basal requirements for trace elements in infants and children and should be used in conjunction with amino acid or glucose solutions or other paediatric admixtures
  • Extensive compatibility and stability data with PN regimens are available upon request from our medical information team: Medical.Information-UK@fresenius-kabi.com

Active Ingredientsper 1mlActive ingredients in 1ml Peditrace correspond to: 
Zinc Chloride 521µg Zinc (Zn) - 250µg
Copper Chloride 2H2053.7µg Copper (Cu) - 20µg
Manganese Chloride 4 H203.60µg Manganese (Mn) - 1µg
Sodium Selenite anhydrous4.38µg Selenium (Se) - 2µg
Sodium Fluoride126µg Fluoride (F) - 57µg
Potassium Iodide1.31µg Iodine (I) - 1µg

 

Peditrace  is  an  integral  part of  the complete intravenous nutrition  of  infants and children.  It is intended to meet basal requirements for trace elements and should be used in conjunction with amino acid or glucose solutions or other paediatric admixtures

See SmPC for full information before prescribing

Peditrace   (Plastic vial)
Unit size  Case qty  Ordering code 
10ml10FYV1981

 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk Adverse events should also be reported to Fresenius Kabi Limited.  Email: Pharmacovigilance.GB@fresenius-kabi.com

 

GB-Ped-2400001  January 2025 

By entering the Healthcare Professional Area you are confirming you are a GB Healthcare Professional. This area contains promotional information. If you are not a Healthcare Professional you will be directed to the Fresenius Kabi GB Corporate website.

GB-NP-2400163 October 2024

I am a Healthcare Professional I am not a Healthcare Professional